|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:associated_with
|
reduction in polio cases
|
|
gptkbp:clinical_trial
|
conducted in 1954
|
|
gptkbp:contains
|
gptkb:inactivated_poliovirus
|
|
gptkbp:developed_by
|
gptkb:Jonas_Salk
|
|
gptkbp:first_introduced
|
gptkb:1955
|
|
gptkbp:historical_significance
|
gptkb:first_effective_polio_vaccine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Salk polio vaccine
|
|
gptkbp:impact
|
global health
|
|
gptkbp:influenced_by
|
public health campaigns
|
|
gptkbp:is_effective_against
|
high
|
|
gptkbp:is_recommended_for
|
gptkb:children
|
|
gptkbp:part_of
|
vaccination schedule
|
|
gptkbp:prevention
|
polio
|
|
gptkbp:produced_by
|
biopharmaceutical companies
|
|
gptkbp:replaced_by
|
oral polio vaccine
|
|
gptkbp:requires
|
cold chain storage
booster doses
|
|
gptkbp:rounds
|
wild poliovirus in many regions
|
|
gptkbp:route_of_administration
|
injection
|
|
gptkbp:successor
|
gptkb:inactivated_polio_vaccine_(IPV)
|
|
gptkbp:suitable_for
|
immunocompromised individuals
|
|
gptkbp:targets
|
gptkb:poliomyelitis
|
|
gptkbp:type
|
inactivated vaccine
|
|
gptkbp:used_in
|
mass immunization campaigns
|
|
gptkbp:bfsParent
|
gptkb:Dr._Jonas_Salk
gptkb:Jonas_Salk
|
|
gptkbp:bfsLayer
|
5
|